Vanda Pharmaceuticals Inc. - 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed on December 4, 2013, reporting events occurring on December 2, 2013. The filing concerns the departure of a senior executive, Robert Repella, Senior Vice President and Chief Commercial Officer.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation and severance arrangements.
Material Changes
Robert Repella's employment will terminate effective January 1, 2014. The material change involves the agreement of specific severance benefits contingent upon the execution of a Separation and Release Agreement.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or general risk factors. The primary contingency noted is the requirement for Mr. Repella to execute a Separation and Release Agreement to receive the outlined benefits.
Key Facts for Investor Verification
- Termination Date: Effective January 1, 2014.
- Severance Cash: 12 months of base salary continuation.
- Bonus: Payment of the full annual target bonus.
- Benefits: COBRA premium coverage and rent/parking support for the remainder of the current lease term.
- Equity: Options vesting period extended by three months; exercisable for six months post-termination.
- Condition: All benefits are subject to the execution of a Separation and Release Agreement.